Christopher Ryan Sullivan
CIK 1810417 · Chief Financial Officer · last filed 2026-05-26
Christopher Ryan Sullivan is a Chief Financial Officer who has filed 19 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for AVTX, was dated May 26, 2026. Across all open-market trades the lifetime net is −$1.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $595.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$595.2K
2
19
-$1.87M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVTX | Chief Financial Officer | 40,323 | $14.76 | $595.2K | -$1.89M | 16 | 2026-05-26 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Interim CFO | 8,049 | $2.93 | $23.6K | $18.3K | 3 | 2021-01-28 |
Recent Filings
19 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-26 | AVTX | Grant (A) | +39,900 | $0 | EDGAR |
| 2026-05-11 | AVTX | Mixed | — | -$265.0K | EDGAR |
| 2026-05-07 | AVTX | Mixed | — | -$570.8K | EDGAR |
| 2026-05-01 | AVTX | Sell (S) | −16,915 | -$222.6K | EDGAR |
| 2026-04-03 | AVTX | Sell (S) | −15,959 | -$270.6K | EDGAR |
| 2026-03-02 | AVTX | Grant (A) | — | $0 | EDGAR |
| 2025-12-12 | AVTX | Tax (F) | −155 | -$636 | EDGAR |
| 2025-04-01 | AVTX | Mixed | +16,915 | -$61.6K | EDGAR |
| 2025-01-30 | AVTX | Grant (A) | — | $0 | EDGAR |
| 2024-08-14 | AVTX | Grant (A) | — | $0 | EDGAR |